Tag: GlobeNewswire

TEL AVIV, Israel, Oct. 07, 2026 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, that CliniQuantum Ltd. (“CliniQuantum”), NeuroThera’s  majority owned subsidiary, reported that its Graphics Processing Unit- accelerated (“GPU”) quantum-simulation platform achieved an approximately 16.8-fold computational acceleration using a single machine with 64 cores (x86_64) and a single NVIDIA T4 Tensor Core GPU compared with the same 64-vCPU machine with only Central Processing Unit (“CPU”) implementation.

The evaluation used a real clinical gene-expression dataset comprising 11 patients and 3,531 gene-expression features, representing a challenging high-dimensional setting in which the number of biological variables greatly exceeds the number of patients.

The algorithm operated by CliniQuantum searched for correlated three-gene configurations across the dataset. The 3,531 genes generated 7,331,162,245 possible three-gene combinations. Using a predefined minimum correlation threshold, the algorithm identified approximately 22.2 million correlated gene triplets.

The analysis required approximately 8.4 hours using 64 vCPUs (virtual CPU), compared with approximately 0.5 hours when accelerated using a single NVIDIA T4 GPU, while producing the same qualifying gene-triplet results.

The benchmark was conducted on an AWS g4dn.16xlarge EC2 machine using an IBM Qiskit Aer GPU-based quantum simulation, with a NVIDIA T4 Tensor Core GPU. The benchmark was designed to evaluate computational performance and did not evaluate or establish the clinical validity, predictive value, or potential utility of any identified gene combinations.

CliniQuantum intends to continue advancing its algorithms toward the analysis of increasingly complex multi-feature configurations and larger biomedical datasets, while progressing its development pathway from simulation and validation toward execution on quantum computing hardware.

About SciSparc Ltd. (Nasdaq: SPRC):

The Company, through its majority-owned subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer’s disease and agitation; and SCI- 210 for the treatment of autism spectrum disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.

About NeuroThera Labs Inc.

NeuroThera is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the potential benefits and advantages of CliniQuantum’s algorithm, its advancement toward the analysis of increasingly complex multi-feature configurations and larger biomedical datasets and progressing its development pathway from simulation and validation toward execution on quantum computing hardware. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, as amended, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055

Potentially accelerates development, assessment, and review for approval by FDA

Sepsis impacts about 1.7 million U.S. adults annually and
contributes to nearly one in three in-hospital deaths

DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that the U.S. Food and Drug Administration (FDA) has granted SeaStar Medical Breakthrough Device Designation for its Selective Cytopheretic Device (SCD) therapy for the treatment of hyperinflammation in adult patients with sepsis or a septic condition. The Breakthrough Device Designation is a regulatory pathway designed to provide for accelerated development, assessment, and review for FDA approval of medical devices and potentially more effective treatments of life-threatening or irreversibly debilitating diseases or conditions. This marks the seventh Breakthrough Device Designation for the SCD therapy thus far across a range of indications.

“This new Breakthrough Device Designation for our SCD therapy continues to exemplify the importance and critical need for an innovative therapy that can effectively treat the hyperinflammation that destroys organs and takes far too many lives each year,” stated Eric Schlorff, CEO of SeaStar Medical. “Our protocol for the ongoing NEUTRALIZE-AKI pivotal clinical trial includes pre-specified statistical analysis of the subset of patients with sepsis or septic like condition, and as such, we expect to have important data to present to the FDA for this indication in the near term. We will move as quickly as possible to submit the relevant data to the FDA and discuss ways to help these patients who today have few options for effectively treating sepsis.”

Sepsis is a medical emergency caused by an overreaction of the immune system to an infection. It often results in an uncontrolled “cytokine storm” that drives widespread immune activation and endothelial injury. In severe cases, this culminates in septic shock, organ dysfunction, and ultimately death. Today, there are no FDA approved therapies to address the dysregulated inflammatory host response in sepsis.

In the U.S. alone, sepsis impacts an estimated 1.7 million adults annually and contributes to nearly one in three in-hospital deaths.  For the patients who survive the acute phase of illness, up to 70% experience post-sepsis syndrome, a debilitating condition characterized by persistent immune dysregulation, cognitive decline, and physical impairments that severely degrade health-related quality of life.  This combination of high acute mortality and enduring chronic morbidity makes sepsis one of the main drivers of cost in the U.S. Healthcare System.

“Sepsis remains one of the most challenging conditions we face in critical care, in large part because treating the infection does not necessarily stop the dysregulated immune response that drives organ injury,” said Kevin Chung, MD, Chief Medical Officer of SeaStar Medical. “The SCD therapy is designed to selectively modulate that response without broadly suppressing the immune system. This Breakthrough Device Designation underscores the significant unmet need in the treatment of sepsis, and we look forward to working with the FDA to advance this therapy for critically ill patients.”

Dr. Chung continued, “This is now the seventh indication for which the SCD has received Breakthrough Device Designation. Each reflects the FDA’s determination that the applicable criteria have been met, including a reasonable expectation that the technology could provide more effective treatment for a life-threatening or irreversibly debilitating condition. We believe the breadth of these designations reinforces the disease-agnostic potential of the SCD platform to address dysregulated inflammation across multiple serious conditions, and we are committed to generating the clinical evidence needed to advance these indications.”

SeaStar Medical also recognizes Col. (Ret.) Ian Stewart, MD, USAF, a talented nephrologist and physician-scientist, who made important contributions to this FDA submission while serving as a Skillbridge Fellow with SeaStar Medical through the Hiring Our Heroes program. SeaStar Medical is proud to have supported this program and grateful for the expertise Dr. Stewart brought to the team.

SeaStar Medical’s seven Breakthrough Device Designations, including its first designation for a pediatric indication, have been granted by CBER for treatment of the following conditions:

• Immunomodulatory dysregulation in adult patients with acute kidney injury (AKI);
• Systemic inflammatory response in adult cardiac surgery;
• Systemic inflammatory response in pediatric cardiac surgery to prevent post-operative adverse complications and outcomes;
• Acute on chronic systolic heart failure and worsening renal function due to cardiorenal syndrome awaiting LVAD implantation;
• Chronic systemic inflammation in end-stage renal disease (ESRD) requiring chronic dialysis;
• Adult patients with Hepatorenal Syndrome (HRS);
• Hyperinflammation in adult patients with sepsis or a septic condition.

About the FDA’s Breakthrough Device Designation

FDA grants Breakthrough Device Designation when a device has the potential to provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions. It must also represent one or more of the following: a) a breakthrough technology, b) a therapeutic treatment where no approved or cleared alternatives exist, c) offer significant advantages over existing approved or cleared alternative, and/or d) the device availability is in the best interest of patients. The Breakthrough Device Designation is designed to provide timely access to medical devices to speed up development, assessment, and review for FDA approval.

About QUELIMMUNE

The QUELIMMUNE^® (SCD-PED) therapy is being commercialized for children with AKI and sepsis or a septic condition weighing 10 kilograms or more who are on antibiotics and being treated in the ICU with RRT.

Data from two clinical trials of the QUELIMMUNE therapy, published in Kidney Medicine, showed a 77% survival rate in patient treated with QUELIMMUNE versus standard of care, representing an approximate 50% reduction in loss of life compared to historical data in this patient population. No dialysis was required for survivors, and 87.5% of survivors had normal kidney function at Day 60 after ICU discharge. In February 2026, data published in the prestigious, peer-reviewed journal, Pediatric Nephrology, highlighted the early experience from the QUELIMMUNE SAVE Registry, a post-approval surveillance registry, evaluating the role of the QUELIMMUNE therapy in the treatment of critically ill pediatric patients with life-threatening Acute Kidney Injury (AKI) and sepsis requiring renal replacement therapy. Observations from the first 21 pediatric patients with AKI and sepsis requiring renal replacement therapy showed no device-related adverse events or infections and no reports of immunosuppressive effects by the device. In addition, preliminary outcomes analyses show a 76% survival rate at Day 28 and Day 60, and a 71% survival rate at Day 90. These new data are on track to validate an observed 50% reduction in patient mortality at 60 days compared to historical data, similar to what was observed in the registration study reported in Kidney Medicine.

The patented technology behind QUELIMMUNE is known as the Selective Cytopheretic Device (SCD) therapy and has broad applications for treating the destructive hyperinflammation that shuts down organ function and causes loss of life.

QUELIMMUNE was approved by FDA under a Humanitarian Device Exemption based on safety and probable benefit.  The effectiveness of this device for this use has not been demonstrated. Adverse reactions observed in clinical studies include hypotension, hypothermia, tachycardia, hyperglycemia, and thrombocytopenia. Additional risks may include blood loss or extracorporeal circuit complications. QUELIMMUNE must be used with citrate anticoagulation. For complete risk information, please see: https://seastarmedical.com/quelimmune 

About the SeaStar Medical Selective Cytopheretic Device (SCD) Therapy

The SCD therapy is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. The SCD therapy is designed for broad applications in multiple acute and chronic kidney and cardiovascular diseases, representing patients who today have no FDA-approved options for treating their disease. Unlike pathogen removal and other blood-purification tools, the SCD therapy is integrated with an existing continuous RRT hemofiltration system to selectively target and transition proinflammatory monocytes to a reparative state and promote activated neutrophils to be less inflammatory. This unique immunomodulation approach may promote long-term organ recovery, eliminate the need for future continuous RRT, including dialysis, and prevent loss of life.  

About NEUTRALIZE-AKI Pivotal Trial

The NEUTRALIZE-AKI (NEUTRophil and monocyte deActivation via SeLective Cytopheretic Device – a randomIZEd clinical trial in Acute Kidney Injury) pivotal trial is evaluating the safety and efficacy of the SCD therapy in 339 adults with AKI in the ICU receiving continuous RRT. The trial’s primary endpoint is a composite of 90-day mortality or dialysis dependency of patients treated with the SCD therapy in addition to continuous RRT as the standard of care, compared with the control group receiving only continuous RRT standard of care. Secondary endpoints include mortality at 28 days, ICU-free days in the first 28 days, major adverse kidney events at Day 90 and dialysis dependency at one year. The study will also include subgroup analyses to explore the effectiveness of the SCD therapy in AKI patients with sepsis and acute respiratory distress syndrome. 

About Acute Kidney Injury (AKI) and Hyperinflammation 

AKI is characterized by a sudden and temporary loss of kidney function and can be caused by a variety of conditions such as severe infections or other septic conditions, severe trauma, surgery, and organ failures. AKI can cause destructive hyperinflammation, which is the overproduction or overactivity of inflammatory effector cells and other molecules that can be toxic. Damage resulting from this destructive hyperinflammation in AKI can progress to other organs, such as the heart or liver, and potentially to multi-organ dysfunction or even failure that could result in worse outcomes, including increased risk of death. Even after resolution, these patients may face complications including chronic kidney disease or end-stage renal disease (ESRD) requiring dialysis. Extreme hyperinflammation may also contribute to added healthcare costs, such as prolonged ICU stays and increased reliance on dialysis and mechanical ventilation.

About SeaStar Medical

SeaStar Medical is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. SeaStar Medical’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening Acute Kidney Injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT) in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting the NEUTRALIZE-AKI pivotal clinical trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.

For more information visit www.seastarmedical.com or visit us on LinkedIn or X.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1955. These forward-looking statements include, without limitation, SeaStar Medical’s expectations with respect to the total addressable market for the SCD applications; the ability of SeaStar Medical to gain market share and generate; the amount and timing of future QUELIMMUNE commercial sales; commercial acceptance of QUELIMMUNE; the ability of SCD to treat patients with AKI and other diseases; the expected regulatory approval process and timeline for commercialization; and the ability of SeaStar Medical to meet the expected timeline. Words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside SeaStar Medical’s control and are difficult to predict. Factors that may cause actual future events to differ materially from the expected results include, but are not limited to: (i) the risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates; (ii) the risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials; (iii) the risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators, (iv) the risk that SeaStar Medical may never achieve or sustain profitability; (v) the risk that SeaStar Medical may not be able to secure additional financing on acceptable terms; (vi) the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations, (vii) the risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical’s products and services, (viii) the risk that SeaStar Medical is unable to secure or protect its intellectual property, and (ix) other risks and uncertainties indicated from time to time in SeaStar Medical’s Annual Report on Form 10-K, including those under the “Risk Factors” section therein and in SeaStar Medical’s other filings with the SEC. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SeaStar Medical assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. 

Contact:  
IR@SEASTARMED.COM

QUELIMMUNE is a registered trademark of SeaStar Medical Holding Corporation.

Matthew Latino appointed CFO; Michael Bishop to continue as senior advisor

DANBURY, Conn., Oct. 07, 2026 (GLOBE NEWSWIRE) — FuelCell Energy, Inc. (Nasdaq: FCEL) today announced that Michael Bishop will transition from his role as Executive Vice President, Chief Financial Officer and Treasurer of the Company. Matthew Latino will succeed him as Executive Vice President, Chief Financial Officer and Treasurer effective October 7, 2026, as part of a planned transition. Bishop, who has served as the Company’s CFO for 15 years during an overall tenure with the Company of more than two decades, will remain with FuelCell Energy as a senior advisor through the Company’s 2027 Annual Meeting of Stockholders to support continuity and the transition.

FuelCell Energy also reaffirmed its previously stated target of achieving positive Adjusted EBITDA results in the fourth quarter of fiscal 2027, subject to the planned increase in annualized production rate, the conversion of awarded capacity backlog into committed backlog, customer delivery schedules and continued execution of the Company’s cost reduction initiatives. The Company remains focused on converting its growing commercial pipeline—driven by demand for reliable, always-on power for AI and data center infrastructure—into durable growth, while scaling manufacturing, advancing customer financing structures and maintaining disciplined capital allocation, liquidity and balance sheet strength.

“Mike has been a steward of this Company through every stage of its journey,” said Jason Few, President and Chief Executive Officer. “Over more than two decades, he led our finance organization through periods that tested our business and our industry while maintaining a clear focus on financial discipline, integrity, the long-term interests of the business, and our commitment to shareholders. His leadership across capital formation, project finance and balance sheet management strengthened our financial foundation and supported the evolution of our strategy. I am grateful for his service and pleased that we will continue to benefit from his perspective during the transition.”

“Serving as CFO of FuelCell Energy has been one of the great privileges of my career,” said Bishop. “I am proud of what our finance team and our colleagues across the Company have accomplished together and of the strong foundation we have built. I have tremendous confidence in Jason, the leadership team, and the Board, and I look forward to supporting a seamless transition and sharing in the Company’s success as a continuing shareholder.”

Latino joins FuelCell Energy from Xylem Inc. (NYSE: XYL), where he served as Senior Vice President, Finance and Segment Chief Financial Officer of its approximately $2 billion Measurement & Control Solutions business. He previously led Xylem’s investor relations function, giving him direct experience engaging the investment community and communicating strategy, performance and long-term value creation. Latino began his career at Deloitte & Touche LLP.

“As we scale, our responsibility to shareholders is to grow with discipline-every megawatt we build and every dollar we deploy must compound value,” Few said. “Matt has led finance for a large-scale industrial technology business, partnered with operating leaders to drive performance, and led investor relations for a global public company. He understands how the market measures execution and how to build the operating rhythm that delivers it. We believe he is the right leader to help us convert a significant commercial opportunity into durable shareholder value.”

“I am honored to join FuelCell Energy at an important point in the Company’s evolution,” said Latino. “The Company has a differentiated technology platform, a strong financial foundation and clear strategic priorities. I look forward to partnering with Jason, the leadership team and the Board to build on the foundation Mike helped establish, maintain rigorous financial discipline, and support the execution and investment decisions required to scale the business and create sustainable value.”

FuelCell Energy, Inc. (Nasdaq: FCEL) is an American clean energy technology company delivering continuous, scalable baseload power for mission-critical applications globally. The company’s fuel cell systems generate electricity directly at the point of use, enabling reliable, low-emissions power for data centers, industrial facilities, utilities, and distributed generation customers. FuelCell Energy delivers commercially proven, modular, utility-scale systems—backed by global fuel cell deployments approaching one gigawatt. Learn more at www.FuelCellEnergy.com. 

Cautionary Language

This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 regarding future events or our future financial performance that involve certain contingencies and uncertainties. The forward-looking statements include, without limitation, statements with respect to the Company’s anticipated financial results and statements regarding the Company’s plans and expectations regarding the continuing development, commercialization and financing of its current and future fuel cell technologies, the Company’s business plans and strategies, the Company’s plan to reduce operating costs, the capabilities of the Company’s products, the Company’s plans and ability to achieve positive Adjusted EBITDA, subject to the planned increase in annualized production rate, the conversion of awarded capacity backlog into committed backlog, customer delivery schedules and continued execution of the Company’s cost reduction initiatives, the Company’s potential sales pipeline, opportunities, and partners, and the markets in which the Company expects to operate. Projected and estimated numbers contained herein are not forecasts and may not reflect actual results. These forward-looking statements are not guarantees of future performance, and all forward-looking statements are subject to risks and uncertainties, known and unknown, that could cause actual results and future events to differ materially from those projected. Factors that could cause such a difference include, without limitation: general risks associated with product development and manufacturing; general economic conditions; changes in interest rates, which may impact project financing; supply chain disruptions; changes in the utility regulatory environment; changes in the utility industry and the markets for distributed generation, distributed hydrogen, and fuel cell power plants configured for carbon capture or carbon separation; potential volatility of commodity prices that may adversely affect our projects; availability of government subsidies and economic incentives for alternative energy technologies; our ability to remain in compliance with U.S. federal and state and foreign government laws and regulations; our ability to maintain compliance with the listing rules of The Nasdaq Stock Market; rapid technological change; competition; the risk that our bid awards (or other non-binding commitments) will not convert to contracts or that our contracts will not convert to revenue; market acceptance of our products; changes in accounting policies or practices adopted voluntarily or as required by accounting principles generally accepted in the United States; factors affecting our liquidity position and financial condition; government appropriations; the ability of the government and third parties to terminate their development contracts at any time; the ability of the government to exercise “march-in” rights with respect to certain of our patents; our ability to successfully market and sell our products internationally; delays in our timeline for bringing commercially viable products to market; our ability to develop additional commercially viable products in the future; our ability to implement our strategy; our ability to reduce our levelized cost of energy and deliver on our cost reduction strategy generally; our ability to protect our intellectual property; litigation and other proceedings; the risk that commercialization of our new products will not occur when anticipated or, if it does, that we will not have adequate capacity to satisfy demand; our need for and the availability of additional financing; our ability to generate positive cash flow from operations; our ability to service our long-term debt; our ability to increase the output and longevity of our platforms and to meet the performance requirements of our contracts; our ability to expand our customer base and maintain relationships with our largest customers and strategic business allies; our ability to reduce operating costs; and our ability to achieve positive Adjusted EBITDA in the future, as well as other risks set forth in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2025. The forward-looking statements contained herein speak only as of the date of this press release. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement contained herein to reflect any change in the Company’s expectations or any change in events, conditions or circumstances on which any such statement is based.

Contacts

Media:
Kathleen Blomquist
kblomquist@fce.com
203.546.5844

Investor Relations:
ir@fce.com

Enrollment completed in Part C of THIO-101 Phase 2 study; 65% of 2026 enrollment target reached in pivotal THIO-104 Phase 3 study

CHICAGO, Oct. 07, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has reached an enrollment milestone with 150 patients treated with ateganosine sequenced with an immune checkpoint inhibitor (CPI) in the ongoing Phase 2 and pivotal Phase 3 clinical trials of its novel telomere-targeting agent ateganosine as a treatment for non-small cell lung cancer (NSCLC).

Enrollment is complete for the Part C of Phase 2 trial, THIO-101, which evaluates ateganosine sequenced with the CPI cemiplimab. MAIA recently announced 90.5% interim disease control (DCR) for the combination therapy in the efficacy evaluable population who had at least one tumor scan after starting treatment. Ateganosine’s measures of efficacy are close to triple the reported outcome for standard-of-care treatment with chemotherapy.

THIO-104 is MAIA’s pivotal Phase 3 trial evaluating ateganosine in sequence with a CPI in third line (3L) NSCLC patients whose disease has progressed following chemotherapy and CPI treatment. MAIA announced the first patient dosed in December 2025, and enrollment and dosing continues to advance at a strong pace. To date, 65 patients have been enrolled. The trial is targeting 100 patients enrolled and dosed by year-end.

“Our Phase 2 THIO-101 trial is on track to be the first completed clinical study of a telomere-targeting agent in the field of cancer drug discovery and treatment,” said Vlad Vitoc, M.D., Founder and CEO of MAIA. “Our strategic focus on third-line NSCLC addresses a critical treatment gap for patients who have progressed after immunotherapy and chemotherapy, with no established standard of care today. Clinical data to date supports ateganosine’s potential to define a new treatment category for this difficult-to-treat population.

“For THIO-104, we have reached 65% of our enrollment target of 100 patients by year-end 2026, and remain on track with our target to conduct an interim analysis in 2027,” Dr. Vitoc added.

The U.S. Food and Drug Administration (FDA) granted Fast Track designation for ateganosine for the treatment of NSCLC in July 2025. The designation allows for more frequent FDA communication, potential rolling review, and eligibility for Accelerated Approval and Priority Review. If approved, ateganosine will hold FDA New Chemical Entity (NCE) five-year marketing exclusivity. An NCE is a small molecule drug with a novel active ingredient that has not been previously approved or marketed.

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About THIO-101 Phase 2 Clinical Trial

THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo^®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo^®) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.

About THIO-104 Phase 3 Clinical Trial

THIO-104 is a multicenter, open-label, randomized Phase 3 clinical trial, designed to evaluate ateganosine’s telomere-targeting anti-tumor activity when followed by PD-(L)1 inhibition in patients with advanced third-line NSCLC who previously did not respond or developed resistance to treatment regimens containing checkpoint inhibitor and/or chemotherapy and have progressed. The trial has two primary objectives: (1) to assess the clinical efficacy of ateganosine compared to investigator’s choice of chemotherapy, using median Overall Survival (OS) as the primary clinical endpoint (2) to evaluate the safety and tolerability of ateganosine in sequential combination with a checkpoint inhibitor. For more information on this Phase 3 trial, please visit ClinicalTrials.gov using the identifier NCT06908304.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com

As the FDA opens the door to non-animal safety testing, VivoSim’s human-relevant models are already helping lower drug costs

SAN DIEGO, Oct. 07, 2026 (GLOBE NEWSWIRE) — VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today celebrated the U.S. Food and Drug Administration’s (FDA) direct final rule updating its regulations to clarify that non-animal methods can be used where appropriate for testing the safety of drugs and biological products intended for human use.

The FDA’s new rule replaces the term “animal tests” with “nonclinical tests” across its regulatory framework, formally opening pathways for NAMs, including human cell-based tests such as those offered by VivoSim.

VivoSim’s liver tissue models are capable of flagging drug candidates likely to cause liver toxicity, side effects like diarrhea, and other issues. Liver toxicity is the leading cause of drug failures and market withdrawals. The company has the ability to meaningfully de-risk a client company’s set of compounds and rule out likely failures prior to its selection of a drug to enter clinical testing.

Drug-induced liver injury (DILI) and gastrointestinal (GI) toxicity remain leading causes of drug candidate attrition. VivoSim’s findings demonstrate how its long-duration, primary human cell-based models can help identify and differentiate these risks earlier in development, successfully ranking clinical safety risks for clients’ drug candidates.

“VivoSim’s NAMkind Models give insights that let our pharma and biotech partners make fewer major mistakes,” said Keith Murphy, VivoSim’s Executive Chairman. “By identifying risky molecules early on in development and moving on to better candidates, they avoid spending $50 to $200M only to learn deep in human clinical trials that their drug’s results in animals were not representative.”

By offering these kinds of insights, VivoSim also is helping with society’s goal of lowering the cost of medicines for patients. The cited costs of up to $2B per approved drug actually reflects the cost of eleven failed drugs for every one approved drug. VivoSim expects such wins to pass on to patients in lower drug costs through more approved drugs, greater competition, and lower pricing needed to recover a fair profit. “If we can help the world get from an 8% success rate in clinical trials to a 30% success rate, it would reduce the cost of drug development by 50%,” Murphy noted.

About VivoSim Labs

VivoSim Labs, Inc. (“VivoSim” and the “Company”), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (“NAM”) models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration (“FDA”) Roadmap to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit www.vivosim.ai.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding the Company’s cash on hand, revenue growth guidance and the Company’s progress in marketing contract research services using NAMs models to pharmaceutical companies. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on July 14, 2026, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on August 12, 2026. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events. 

Contact(s):
Investor Relations
info@vivosim.ai
VivoSim Labs, Inc.

NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) — ExlService Holdings, Inc. (NASDAQ: EXLS), a global data and AI company, will release financial results for the third quarter ended September 30, 2026, on Tuesday, October 27, 2026, after the market closes. An earnings news release, investor fact sheet and presentation will be published on the company’s investor relations website offering an overview of the financial results.

The company will host a conference call at 10:00 a.m. EDT the following day, Wednesday, October 28, 2026, with Chairman and Chief Executive Officer Rohit Kapoor and Executive Vice President and Chief Financial Officer Maurizio Nicolelli, who will provide insights into the company’s operational and financial results.

To listen to video live webcast or to participate in the call, please register here. A replay of the webcast will be available for approximately one year.

About EXL 

EXL (NASDAQ: EXLS) is a global data and AI company that offers services and solutions to reinvent client business models, drive better outcomes and unlock growth with speed. EXL propels enterprises to go beyond AI ambition to impact by combining the power of data, AI, and deep industry context with trusted execution. Our clients include the world’s leading corporations across insurance, healthcare, banking and capital markets, retail, communications and media, and energy and infrastructure, among others. EXL was founded in 1999 with the core values of innovation, collaboration, excellence, integrity and respect. We are headquartered in New York and have approximately 68,000 employees spanning six continents. For more information, visit http://www.exlservice.com.  

Contact:
Andrew Thut
Head of Investor Relations and Capital Markets 
ir@exlservice.com

AVENTURA, Fla., Oct. 07, 2026 (GLOBE NEWSWIRE) — Safe Pro Group Inc. (Nasdaq: SPAI) (“Safe Pro” or the “Company”), a developer of artificial intelligence (AI)-enabled defense, security, and situational awareness solutions, today announced preliminary, unaudited revenue expectations for the third quarter ended September 30, 2026.

The Company expects third-quarter 2026 revenue to increase by over 2,300% to more than $2.5 million, compared with $101,422 in the third quarter of 2025 driven by the receipt of multiple U.S. Government subcontract awards supporting the U.S. Army and U.S. Air Force. For the nine months ended September 30, 2026, the Company expects revenue to increase by over 1,200% to more than $5.0 million compared with $378,977 in the same period of 2025. These figures are preliminary, unaudited estimates that remain subject to change upon completion of the Company’s quarterly closing and review procedures.

The significant quarterly revenue growth is being driven by increasing deliveries of the Company’s patented AI-powered software and edge-based battlefield intelligence solutions to multiple U.S. Government prime contractors.

In the third quarter, the Company successfully completed participation in multiple U.S. Army exercises and technology demonstrations driving new business development efforts. The Company is seeing significantly increased activity across the U.S. government, including with multiple divisions within the U.S. Army, the U.S. Air Force, and most recently, with the U.S. Department of State.

• Based on Preliminary Unaudited Financial Data, Third Quarter 2026 Revenue Growth Expected to be More Than 2,300% Year-over-Year
  • Safe Pro continues to deliver against U.S. Army and recent government contract awards for its AI software powering edge-based compute solutions, representing more than $5 million in aggregate awarded contract value year-to-date.
  • Deliveries during Q3 included work under a $1.3 million subcontract from a U.S. defense prime contractor to integrate real-time AI threat detection onto autonomous unmanned ground vehicles and a $780,000 U.S. Army award for a package including its NODE AI edge-processing systems and Blue UAS drones.
  • Third quarter 2026 revenue represents increase of approximately 88% on a sequential basis compared with the second quarter of 2026.
• Military and Dual-Use Pipelines Expanding
  • Revenue reflects growing demand across Safe Pro’s suite of AI products including for threat detection and mapping, edge compute, software licensing, and operational services and support.
  • The Company has expanded its relationships across the government with existing customers such as the U.S. Army under a Cooperative Research and Development Agreement (CRADA), potentially extending its technology to use cases beyond the military into broad commercial markets and adding new relationships such as with the U.S. Department of State, where the Company was awarded a subcontract for its AI-powered demining software supporting demining activities in Ukraine. The Company believes that the use of AI-powered tools will be critical to the massive efforts required to restore Ukraine’s vital agricultural sector, recover its rare earth minerals, and support its reconstruction.
• Strong Balance Sheet Supports Continued Growth
  
  • Rapid execution against awarded government contracts is expected to drive high margin revenue growth and contribute to a significant increase in accounts receivable, which the Company believes, subject to customary government payment processes, will provide improved cash flows and support its operating and technology development activities through 2027.
  • The Company continues to maintain significant cash reserves and no long-term debt.

“Expected third-quarter revenue of more than $2.5 million nearly doubles our second-quarter result, and nine-month revenue of more than $5.0 million is already more than eight times our full-year 2025 revenue,” said Dan Erdberg, Chairman and Chief Executive Officer of Safe Pro Group Inc. “The growth reflects repeat orders from U.S. Army customers and our first awards from new agencies, including the Department of State and U.S. Air Force. Our priority for the fourth quarter and 2027 is growing deployments of our patented American AI technologies across multiple branches of the US Government and our allies.”

Built on battle-tested AI, Safe Pro’s technology converts raw visual data collected by drones into rapidly shareable, high-resolution 2D and 3D maps, providing a novel and scalable approach to situational awareness on the battlefield. Safe Pro’s AI dataset includes more than 3.1 million drone images and over 58,526 confirmed detections collected in over 39,777 acres of land in Ukraine. For more information about Safe Pro’s real-world landmine and UXO detections, visit: https://safeproai.com/landmine-detections/.

For information about Safe Pro Group, its subsidiaries, and technologies, please visit https://safeprogroup.com and connect with us on LinkedIn, Facebook, and X.

About Safe Pro Group Inc.
Safe Pro Group Inc. (Nasdaq: SPAI) is a mission-driven technology company delivering AI-enabled security and defense solutions. Through cutting-edge platforms like SPOTD, Safe Pro provides advanced situational awareness tools for defense, humanitarian, and homeland security applications globally. The Company is a leading provider of artificial intelligence (AI) solutions specializing in drone imagery processing and mapping, leveraging commercially available off-the-shelf drones with its proprietary machine learning and computer vision technology to enable rapid identification of explosive threats, providing a safer and more efficient alternative to traditional human-based analysis methods. Built on a cloud-based ecosystem and powered by Amazon Web Services (AWS), Safe Pro Group’s scalable platform targets multiple markets, including commercial, government, law enforcement, and humanitarian sectors where its Safe Pro AI software, Safe-Pro USA protective gear, and Airborne Response drone-based services can work in synergy to deliver safety and operational efficiency. For more information on Safe Pro Group Inc., please visit https://safeprogroup.com.

Forward-Looking Statements
Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements relate to future events, future expectations, plans and prospects and in this press release include, without limitation, the Company’s projected more than 2,300% year-over-year revenue increase for Q3 2026, its projected approximately 88% sequential revenue increase compared with Q2 2026, and its projected more than 1,200% year-over-year revenue increase for the first nine months of 2026 with total revenue expected to exceed $5.0 million, which are preliminary, unaudited financial data that may be revised upon completion of the Company’s quarterly review process, Safe Pro’s ability to generate revenue from the sales of its products, its ability to support current and future customers, statements regarding commercialization and recurring revenue generation, market opportunities, business momentum, the Company’s contract pipeline and expected continued growth, the expansion of AI offerings to new platforms and applications, and the expected contribution of the Company’s government contracts to revenue. Although Safe Pro Group believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Safe Pro Group has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth under Item 1A. in the Company’s most recently filed Form 10-K and updated from time to time in the Company’s Form 10-Q filings and in other filings with the Securities and Exchange Commission (the “SEC”), copies of which may be obtained from the SEC’s website at www.sec.gov. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to: the risk that the Company’s preliminary, unaudited estimated financial results for the third quarter and nine months ended September 30, 2026 may differ materially from the Company’s final reported results upon completion of its quarterly closing, review, and audit procedures; the Company’s limited operating history and history of losses; the Company’s ability to successfully execute on government contracts; risks related to government contracting including contract modifications, delays, or cancellations; risks related to concentration of revenue from a limited number of government programs; risks related to changes in government budgets, spending priorities, sequestration, or continuing resolutions that could reduce or delay funding for the Company’s programs; the Company’s ability to scale operations; market acceptance of the Company’s products; competition; technological changes; the Company’s reliance on third-party technology providers including AWS; risks related to international operations, including geopolitical risks associated with the ongoing conflict in Ukraine; regulatory compliance; and general economic conditions. Any forward-looking statements contained in this press release speak only as of its date. Safe Pro Group undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.

Media Relations for Safe Pro Group Inc.:
media@safeprogroup.com

Investor Contact:
Ankit Hira, Managing Director
Solebury Strategic Communications for Safe Pro Group Inc.
spai@soleburystrat.com

Si829x platform with ProVCD™ technology moves from development to pre-production release for EV traction inverters

IRVINE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) — Skyworks Solutions, Inc. (Nasdaq: SWKS), an innovator of high-performance analog and mixed-signal semiconductors, today announced that its Si829x isolated safety gate driver with ProVCD™ technology has completed AEC-Q100 automotive qualification and is ready for advanced prototyping. Samples, tools, user guides, and application notes are available now. Designed for scalable, high-performance inverter architectures, the Si829x supports both SiC FETs and IGBTs while helping customers improve efficiency, simplify system design, and reduce system cost in applications ranging from automotive drivetrains to safety-critical electric vertical take-off and landing (eVTOL) systems.

AEC-Q100 Qualified and Ready for Evaluation

With AEC-Q100 qualification completed, the Si829x is now positioned to support customers for initial product evaluation through pre-production prototypes. Samples are available today, giving customers a qualified, prototype-ready path to design-in.

The Si829x was designed to support customer functional safety system designs rated up to ASIL D, subject to system-level implementation and validation, to deliver the robustness required for EV traction inverters and other safety critical motor control applications. Its integrated protection features include:

• Extensive diagnostic fault coverage, notification and management
• Comprehensive safety mechanisms including power-up self-checks and safe state enforcement – a functional safety manual is available today
• Advanced isolation technology certified by multiple independent organizations for enhanced safety and reliability

With applications in battery electric vehicles, hybrid electric vehicles, eAgriculture, eTrucking, robotaxis, and exciting new segments like eVTOL aircraft, Si829x is a comprehensive choice among isolated gate drivers for safety-critical advanced propulsion systems.

Full Documentation and Development Tools Now Available

Alongside qualification, Skyworks has prepared the complete technical resource set for the Si829x, including datasheet, technical reference manual, functional safety manual and application notes. This resource set, available under NDA, gives design teams comprehensive technical documentation to evaluate, integrate and validate the part.

Skyworks has also released customer-facing development tools, including two evaluation board kits, companion GUI software and complex device driver (CDD) software, designed to shorten development cycles and reduce time-to-market.

A New Approach to Gate Drive Control

Unlike conventional voltage-mode gate drivers, the Si829x uses ProVCD™, which is Skyworks’ second-generation variable current drive that delivers high resolution gate waveform shaping and cycle-by-cycle control through a digital interface. This approach enables:

• Precise 15 Amp 3-phase turn-on and turn-off current waveform control
• Switching-loss reductions of up to 44% in Skyworks testing, compared with voltage-mode gate drive
• Reduced electromagnetic interference (EMI) and filtering requirements
• Improved thermal efficiency through multiple packaging options
• Smaller PCB footprint and potential system-level cost savings

Together, these benefits allow manufacturers to increase inverter efficiency while simplifying system design and accelerating development cycles.

“Si829x gives customers a qualified path from evaluation to advanced prototypes,” said Mario Battello, vice president of product line management at Skyworks. “The ProVCD™ platform combines software-configurable performance with the safety, isolation and design flexibility needed to standardize inverter designs for EVs, eVTOL, and eAgriculture, and accelerate development for high power motor applications like datacenter cooling and AI power supplies.”

Platform Scalability and Design Flexibility

The Si829x is designed as a configurable platform, allowing engineers to adjust gate drive parameters through software rather than fixed hardware components. This configurability supports:

• Design reuse across multiple vehicle platforms
• Faster development and validation cycles
• Greater flexibility to optimize performance, efficiency and cost
• Vendor-agnostic compatibility across power semiconductor technologies

By supporting both SiC FETs and IGBTs within a single gate driver platform that integrates a VPOS regulator, bipolar gate drive voltages are provided without the need for additional, external bias supplies.

Si829x availability

The Si829x platform is now available for sampling. To learn more, including product features, package options and design resources, visit skyworks.com/go/si829x.

About Skyworks

Skyworks® is a global leader in high-performance RF, precision timing, power management and mixed-signal solutions that power the intelligent, connected world. Through deep engineering expertise, Skyworks helps customers address rising complexity and deliver seamless connectivity across smartphones, vehicles, networks and critical infrastructure.

From defense and aerospace systems to the connected edge, AI infrastructure and next-generation automotive platforms, Skyworks provides the essential technologies that connect, synchronize and power physical AI, as intelligence moves out of the data center and into the real world. Harnessing decades of technical leadership and trusted partnerships across the technology ecosystem, Skyworks helps the world’s leading innovators bring next-generation products and services to market.

Skyworks is a member of the S&P 500® market index (Nasdaq: SWKS). For more information, please visit www.skyworks.com.

Safe Harbor Statement

Any forward-looking statements contained in this press release are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include without limitation information relating to future events, results and expectations of Skyworks. Forward-looking statements can often be identified by words such as “anticipates,” “expects,” “forecasts,” “intends,” “believes,” “plans,” “may,” “will” or “continue,” and similar expressions and variations or negatives of these words. Actual events and/or results may differ materially and adversely from such forward-looking statements as a result of certain risks and uncertainties including, but not limited to, our ability to timely and accurately predict market requirements and evolving industry standards and to identify opportunities in new markets; our ability to develop, manufacture, and market innovative products and avoid product obsolescence; our ability to compete in the marketplace and achieve market acceptance of our products; the level of widespread deployment or adoption of commercial 5G networks, AI and other new technologies; the availability and pricing of third-party semiconductor foundry, assembly and test capacity, raw materials and supplier components; the quality of our products; our products’ ability to perform under stringent operating conditions; and other risks and uncertainties identified in the “Risk Factors” section of Skyworks’ most recent Annual Report on Form 10-K (and/or Quarterly Report on Form 10-Q) as filed with the Securities and Exchange Commission (“SEC”). Copies of Skyworks’ SEC filings can be obtained, free of charge, on Skyworks’ website (www.skyworksinc.com) or at the SEC’s website (www.sec.gov). Any forward-looking statements contained in this press release are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

Note to Editors: ProVCD™, SelVCD™, Skyworks and the Skyworks symbol are trademarks or registered trademarks of Skyworks Solutions, Inc., or its subsidiaries in the United States and other countries. Third-party brands and names are for identification purposes only and are the property of their respective owners.

Media Relations:         Constance Griffiths (949) 230-4867         Constance.Griffiths@skyworks.com

Investor Relations: Raji Gill (949) 508-0973 Raji.Gill@skyworks.com

NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) — Virtu Financial, Inc. (NYSE:VIRT), a leading provider of global, multi-asset financial services that delivers liquidity and innovative, transparent products across the complete investment cycle to the global markets, will announce its results for the third quarter of 2026 on Thursday, November 5, 2026, before the US market open.

Virtu will host a conference call to discuss the company’s financial results at 8:00 AM (ET). A live webcast of the event will be available and archived on the Investor Relations section of the company’s website at https://ir.virtu.com/events-presentations. The call will be open to the public.

About Virtu Financial, Inc.
Virtu is a leading provider of financial services and products that leverages cutting-edge technology to deliver liquidity to the global markets and innovative, transparent trading solutions to its clients. Leveraging its global market making expertise and infrastructure, Virtu provides a robust product suite including offerings in execution, liquidity sourcing, analytics and broker-neutral, multi-dealer platforms in workflow technology. Virtu’s product offerings allow clients to trade on hundreds of venues across 50+ countries and in multiple asset classes, including global equities, ETFs, foreign exchange, futures, fixed income, cryptocurrency and myriad other commodities. In addition, Virtu’s integrated, multi-asset analytics platform provides a range of pre-, intra-, and post-trade services, data products and compliance tools that clients rely upon to invest, trade and manage risk across global markets.

Contact:

Investor Relations
Matthew Sandberg
investor_relations@virtu.com

SCOTTSDALE, Ariz., Oct. 07, 2026 (GLOBE NEWSWIRE) — WillScot Holdings Corporation (“WillScot” or the “Company”) (Nasdaq: WSC), a leader in innovative temporary space solutions, today announced that, as part of its ongoing board refreshment efforts, the WillScot Board of Directors (the “Board”) has unanimously elected Donald (Don) Slager as an independent director effective October 7, 2026.

Worthing Jackman, Executive Chairman of WillScot, commented, “We are fortunate to welcome Don to WillScot’s Board. Our ongoing refreshment process is focused on maintaining the right mix of skills, experience and perspectives to support the Company’s long-term success. Don’s strategic and operational leadership, corporate governance expertise and experience guiding businesses through transformation and complex operating environments will further strengthen the Board and provide valuable perspective as WillScot pursues the opportunities ahead.”

Tim Boswell, CEO of WillScot, commented, “Don has a decades-long record of leading public companies through transformation and creating shareholder value. His experience guiding businesses through periods of growth and evolution will provide valuable strategic insight as we execute our long-term objectives and realize the full potential of WillScot. I have enjoyed getting to know Don and look forward to working with him as we strengthen execution and deliver sustainable value for our shareholders.”

Mr. Slager has been appointed to serve on the Audit Committee and Compensation Committee of the Board.

About Donald (Don) Slager

Mr. Slager served as President and Chief Executive Officer of Republic Services, Inc. (Republic) (NYSE: RSG), a leader in the environmental services industry, from 2011 until his retirement in 2021. Before becoming Chief Executive Officer, he served as Republic’s President and Chief Operating Officer beginning in December 2008. He previously served as President and Chief Operating Officer of Allied Waste Industries, Inc. (Allied Waste) from 2005 until its merger with Republic in 2008 and as Allied Waste’s Executive Vice President and Chief Operating Officer from 2003 to 2004. Mr. Slager also served as a Director of Republic from 2010 to 2021.

An experienced public company director, Mr. Slager currently serves on the boards of Martin Marietta Materials, Inc. (NYSE: MLM) and Eastman Chemical Company (NYSE: EMN). At Martin Marietta, a leading supplier of aggregates and other building materials, he is Lead Independent Director and a member of the Executive Committee and Nominating & Corporate Governance Committee, and Chair of the Management Development & Compensation Committee. At Eastman Chemical, a global specialty materials company, he is an independent director and a member of the Audit Committee, Finance Committee, and Environmental, Safety & Sustainability Committee.

About WillScot

WillScot (Nasdaq: WSC) is a leading provider of innovative turnkey space solutions in North America, helping customers keep projects moving and operations running. The Company partners with critical industries including construction, manufacturing, healthcare, government, energy and education to deliver the right solutions coupled with a high level of customer service. WillScot’s comprehensive portfolio of products – including modular complexes, dry and cold storage containers, blast-resistant buildings, clearspan industrial structures, fencing, and add-on furnishings and equipment – is customizable and flexible to support any project need. Headquartered in Scottsdale, Ariz., WillScot operates from a network of approximately 240 branch locations in the U.S., Canada, and Mexico.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. The words “estimates,” “expects,” “anticipates,” “believes,” “forecasts,” “plans,” “intends,” “may,” “will,” “should,” “shall,” “outlook,” “guidance,” “see,” “have confidence” and variations of these words and similar expressions identify forward-looking statements, which are generally not historical in nature. Forward-looking statements are subject to a number of risks, uncertainties, assumptions and other important factors, many of which are outside our control, which could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Although the Company believes that these forward-looking statements are based on reasonable assumptions, they are predictions and we can give no assurance that any such forward-looking statement will materialize. Any forward-looking statement speaks only at the date on which it is made, and the Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contact Information

Investor inquiries:
Charlie Wohlhuter
Investors@willscot.com

Media inquiries:
Juliana Welling
Media@willscot.com